Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of the National Cancer Institute

• Publication date

  2014-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/jnci/djt459PMID 24586107
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bortezomib in the treatment of mantle cell lymphoma.

  2015cited by this paper
• A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)

  2013cited by this paper
• Bortezomib Is Cytotoxic to the Human Growth Plate and Permanently Impairs Bone Growth in Young Mice

  2012cited by this paper
• Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.

  2012cited by this paper
• Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

  2012cited by this paper
• Starvation, detoxification, and multidrug resistance in cancer therapy.

  2012cited by this paper
• Humanin preserves endothelial function and prevents atherosclerotic plaque progression in hypercholesterolemic ApoE deficient mice.

  2011cited by this paper
• Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo

  2011cited by this paper
• Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment.

  2011cited by this paper
• Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates

  2010cited by this paper
• Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium

  2010cited by this paper
• Opposing roles of insulin-like growth factor binding protein 3 and humanin in the regulation of testicular germ cell apoptosis.

  2010cited by this paper
• Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

  2010cited by this paper
• The neurosurvival factor Humanin inhibits beta-cell apoptosis via signal transducer and activator of transcription 3 activation and delays and ameliorates diabetes in nonobese diabetic mice.

  2010cited by this paper
• Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130.

  2009cited by this paper
• Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells

  2009cited by this paper
• Humanin: A Novel Central Regulator of Peripheral Insulin Action

  2009cited by this paper
• Bortezomib reverses a post‐translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma

  2009cited by this paper
• Embryonal neural tumours and cell death

  2009cited by this paper
• Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo

  2008cited by this paper
• Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program

  2008cited by this paper
• Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.

  2008cited by this paper
• Proteasome inhibition therapies in childhood cancer

  2008cited by this paper
• Endochondral ossification: how cartilage is converted into bone in the developing skeleton.

  2008cited by this paper
• Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20

  2008cited by this paper
• S14G-Humanin ameliorates Abeta25-35-induced behavioral deficits by reducing neuroinflammatory responses and apoptosis in mice.

  2008cited by this paper
• Bortezomib for the Treatment of Mantle Cell Lymphoma

  2007cited by this paper
• Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.

  2007cited by this paper
• Dose translation from animal to human studies revisited

  2007cited by this paper
• Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma.

  2007cited by this paper
• Chronic health conditions in adult survivors of childhood cancer.

  2006cited by this paper
• Inhibition of the proteasomal function in chondrocytes down-regulates growth plate chondrogenesis and longitudinal bone growth.

  2006cited by this paper
• Humanin Is a Novel Neuroprotective Agent Against Stroke

  2006cited by this paper
• Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.

  2006cited by this paper
• Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.

  2006cited by this paper
• Proteasome inhibition as a novel therapeutic target in human cancer.

  2005cited by this paper
• Of mice and men

  2005cited by this paper
• Humanin Binds and Nullifies Bid Activity by Blocking Its Activation of Bax and Bak*

  2005cited by this paper
• Cytoprotective Peptide Humanin Binds and Inhibits Proapoptotic Bcl-2/Bax Family Protein BimEL*

  2005cited by this paper
• Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

  2004cited by this paper
• Development of the Proteasome Inhibitor Velcade™ (Bortezomib)

  2004cited by this paper
• Long‐term Complications Following Childhood and Adolescent Cancer: Foundations for Providing Risk‐based Health Care for Survivors

  2004cited by this paper
• Pharmacology, pharmacokinetics, and practical applications of bortezomib.

  2004cited by this paper
• The proteasome: a suitable antineoplastic target

  2004cited by this paper
• Interleukin-1beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones.

  2004cited by this paper
• Interleukin‐1β and TNF‐α Act in Synergy to Inhibit Longitudinal Growth in Fetal Rat Metatarsal Bones

  2004cited by this paper
• Humanin peptide suppresses apoptosis by interfering with Bax activation

  2003cited by this paper
• Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

  2003cited by this paper
• Humanin improves impaired metabolic activity and prolongs survival of serum-deprived human lymphocytes

  2003cited by this paper
• The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.

  2002cited by this paper
• Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

  2002cited by this paper
• A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ

  2001cited by this paper
• Bone development.

  2000cited by this paper
• Chondrocyte Differentiation in a Rat Mesenchymal Cell Line

  1999cited by this paper
• Chemotherapeutic agents used in the treatment of childhood malignancies have direct effects on growth plate chondrocyte proliferation.

  1998cited by this paper
• Apoptosis of Ewing's sarcoma cells is accompanied by accumulation of ubiquitinated proteins.

  1997cited by this paper
• Lessons from the discovery of the ubiquitin system.

  1996cited by this paper
• Lessons from the discovery ofthe ubiquitin system

  1996cited by this paper
• Growth and growth hormone in children during and after therapy for acute lymphoblastic leukaemia

  1993cited by this paper
• Growth after radiotherapy and chemotherapy in children with leukemia or lymphoma.

  1992cited by this paper
• Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia.

  1991cited by this paper
• Growth failure and growth-hormone deficiency after treatment for acute lymphoblastic leukaemia.

  1987cited by this paper
• Isolation of bone cell clones with differences in growth, hormone responses, and extracellular matrix production

  1982cited by this paper
• Pharmacology, pharmacokinetics, and practical applications of bortezomib.

  1964cited by this paper

• Humanin improves bone health in a glucocorticoid-treated mouse model of Duchenne muscular dystrophy

  2026cites this paper
• Humanin variants aggregate to produce different fibril morphologies

  2025cites this paper
• The proteasome subunit psmb1 is essential for craniofacial cartilage maturation and morphogenesis

  2024cites this paper
• The Relative Efficacy of Available Proteasome Inhibitors in Preventing Muscle Contractures Following Neonatal Brachial Plexus Injury

  2024cites this paper
• Humanin Treatment Protects Against Venetoclax-Induced Bone Growth Retardation in Ex Vivo Cultured Rat Bones

  2024cites this paper
• Stability Determination of Intact Humanin-G with Characterizations of Oxidation and Dimerization Patterns

  2023cites this paper
• Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives

  2023cites this paper
• Exploring the potential of humanin as a biomarker for early breast cancer detection: a study of serum levels and diagnostic performance

  2023cites this paper
• Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth

  2023cites this paper
• Revolutionalizing the age old conventional treatment of psoriasis: An animal based comparative study between methylprednisolone and different doses of a novel anti-oxidant humanin analogue (HNG).

  2022cites this paper
• The Molecular Structure and Role of Humanin in Neural and Skeletal Diseases, and in Tissue Regeneration

  2022cites this paper
• Mitochondria-derived peptides in aging and healthspan

  2022cites this paper
• Peptides GWN and GW protect kidney cells against Dasatinib induced mitochondrial injury in a SIRT1 dependent manner

  2021cites this paper
• Humanin Promotes Tumor Progression in Experimental Triple Negative Breast Cancer

  2020cites this paper
• Mechanisms of protection of retinal pigment epithelial cells from oxidant injury by humanin and other mitochondrial-derived peptides: Implications for age-related macular degeneration

  2020cites this paper
• Humanin: A mitochondrial-derived peptide in the treatment of apoptosis-related diseases.

  2020cites this paper
• Timing of proteasome inhibition as a pharmacologic strategy for prevention of muscle contractures in neonatal brachial plexus injury

  2020cites this paper
• Humanin is a novel regulator of Hedgehog signaling and prevents glucocorticoid‐induced bone growth impairment

  2019cites this paper
• Repurposing Disulfiram as an Anti-Cancer Agent: Updated Review on Literature and Patents.

  2019cites this paper
• The humanin analogue (HNG) prevents temozolomide-induced male germ cell apoptosis and other adverse effects in severe combined immuno-deficiency (SCID) mice bearing human medulloblastoma.

  2019cites this paper
• MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus.

  2019cites this paper
• Mitochondrial-derived peptide humanin as therapeutic target in cancer and degenerative diseases

  2019cites this paper
• Prevention of growth failure caused by glucocorticoids and inflammation

  2019cites this paper
• Role of mitochondrial-derived peptide humanin as a therapeutic target in cancer and neurodegeneration

  2019cites this paper
• Interaction of Insulin-Like Growth Factor-Binding Protein 3 With Hyaluronan and Its Regulation by Humanin and CD44.

  2018cites this paper
• Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.

  2018cites this paper
• Baculovirus-based gene silencing of Humanin for the treatment of pituitary tumors

  2018cites this paper
• Mitochondrial Toxicity Induced by Chemotherapeutic Drugs

  2018cites this paper
• Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans

  2018cites this paper
• Targeting NEDD8 Conjugation for Therapeutic Gain in Acute Lymphoblastic Leukemia

  2017cites this paper
• Humanin G (HNG) protects age-related macular degeneration (AMD) transmitochondrial ARPE-19 cybrids from mitochondrial and cellular damage

  2017cites this paper
• Humanin inhibits apoptosis in pituitary tumor cells through several signaling pathways including NF-κB activation

  2017cites this paper
• The Impact of Cancer Treatments on Aging

  2016cites this paper
• Humanin: Functional Interfaces with IGF-I.

  2016cites this paper
• Novel use of clinical drugs: Deubiquitinase inhibitor auranofin and disulfiram show synergistic anti-tumor effects in vitro and in vivo

  2016cites this paper
• Bortezomib for the treatment of acute lymphoblastic leukemia

  2016cites this paper
• Combined therapeutic effects of bortezomib and anacardic acid on multiple myeloma cells via activation of the endoplasmic reticulum stress response.

  2016cites this paper
• The Mitochondrial-Derived Peptide Humanin Protects RPE Cells From Oxidative Stress, Senescence, and Mitochondrial Dysfunction

  2016cites this paper
• The Potent Humanin Analogue (HNG) Protects Germ Cells and Leucocytes While Enhancing Chemotherapy-Induced Suppression of Cancer Metastases in Male Mice.

  2015influential citation
• Rat Humanin is encoded and translated in mitochondria and is localized to the mitochondrial compartment where it regulates ROS production.

  2015cites this paper
• Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo

  2015cites this paper
• The effects of humanin and its analogues on male germ cell apoptosis induced by chemotherapeutic drugs

  2015cites this paper
• Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.

  2015cites this paper
• Humanin and Age-Related Diseases: A New Link?

  2014influential citation
• New role for the mitochondrial peptide humanin: protective agent against chemotherapy-induced side effects.

  2014cites this paper
• IGF-I regulates the age-dependent signaling peptide humanin

  2014cites this paper
• Protective Effects of Humanin and Calmodulin-Like Skin Protein in Alzheimer’s Disease and Broad Range of Abnormalities

  2014cites this paper